The groundbreaking procedure, led by a collaborative team from Leeds Teaching Hospitals NHS Trust and the University of Leeds, utilised OsStic, a new material developed by Biomimetic Innovations Ltd. This material is designed to be injected into bone gaps and weakened areas, providing support and encouraging natural bone growth. It holds the potential to revolutionise the treatment of severe bone injuries, particularly complex fractures like the lateral tibial plateau fracture experienced by the first patient.
Professor Peter Giannoudis MBE, Clinical Professor at the University of Leeds and Honorary Consultant at the Leeds General Infirmary, spearheaded the study and the surgical team. He highlighted the multidisciplinary effort involved, stating, "By combining advanced surgical expertise with this innovative new technology OsStic, we were able to accurately reconstruct the damaged joint and restore its structural integrity." The patient's rapid rehabilitation, returning home just one day after surgery, was noted as particularly encouraging.
“"Innovations such as this have the potential to transform the way we treat complex fractures, offering surgeons new options where conventional techniques may have limitations and, ultimately, helping patients recover more quickly and return to their daily lives sooner."
This trial was made possible through close collaboration between researchers, clinical staff, academics, and support teams across Leeds, including the NIHR Clinical Research Facility: Leeds and the NIHR Biomedical Research Centre. This partnership has previously delivered world-first clinical trials in various medical fields.
Professor Chris Twelves, Director of the NIHR Clinical Research Facility: Leeds, emphasised the power of collaboration between the NHS, academia, research infrastructure, and industry. He stated, "This achievement is the result of extraordinary teamwork from research nurses, physiotherapists, clinical research fellows, specialty registrars, consultant clinicians and research support staff, all working towards a shared goal."
Paul Burke, Managing Partner of Biomimetic Innovations Ltd, described the first-in-human use of OsStic™ as a major milestone for the company, expressing excitement about partnering with leading clinicians to improve orthopaedic care outcomes.




